Clinical Trial Update: Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine combined with imatinib mesylate in pemetrexed-pretreated malignant pleural mesothelioma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Mesothelioma, Malignant | Phase 2 | Status: COMPLETED